Target intelligence / Profile preview

Aspartylglucosaminidase (AGA)

Target
AGA
Molecular classification
Enzyme, Amidohydrolase, Lysosomal enzyme
01

Overview

Aspartylglucosaminidase is a lysosomal amidohydrolase enzyme responsible for cleaving the bond between asparagine and N-acetylglucosamine in N-linked glycoproteins during the final steps of lysosomal degradation. It is synthesized as a single precursor chain, which undergoes post-translational cleavage to produce α and β subunits that assemble into a functional heterotetramer. Deficiency of this enzyme activity, typically due to mutations in the AGA gene, leads to aspartylglucosaminuria—a lysosomal storage disorder characterized by progressive intellectual disability and motor impairments resulting from disrupted glycoprotein catabolism and subsequent accumulation in neural and other tissues[1][2][3][4][5].

Other names
GlycosylasparaginaseN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseN4-(N-acetyl-beta-glucosaminyl)-L-asparagine amidaseAspartylglucosylamine deaspartylaseASRGGAAGU
02

Biological functions

Catabolism of N-linked glycoproteinsLysosomal degradation of oligosaccharidesCleavage of asparagine-N-acetylglucosamine bond
03

Disease associations

Lysosomal storage diseaseNeurodegenerative disease (aspartylglucosaminuria, a progressive disorder with mental and motor decline)
04

Safety considerations

Progressive neurodegeneration due to loss-of-function mutationsno direct pharmacologic safety concerns but enzyme replacement or gene therapies are investigational and may have immunogenicity or delivery challenges
05

Biomarkers

Genetic testing for AGA mutations (for diagnosis of aspartylglucosaminuria)Enzyme activity assays (for diagnosis and carrier screening)

Beyond the preview

Go deeper on Aspartylglucosaminidase (AGA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspartylglucosaminidase (AGA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call